On the relationship between docking scores and protein conformational changes in HIV-1 protease.

J Mol Graph Model

Department of Medicinal Chemistry, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran; Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medicinal Sciences, Shiraz, Iran.

Published: September 2019

We present a detailed investigation of the effect of the crystallographic structure of the HIV-1 protease (PR) on the binding energy of different classes of inhibitors obtained from docking simulations. The crystal structures of 222 HIV-1 proteases (in wild-type and mutant forms) and 202 inhibitors were downloaded from appropriate databases. A cross-docking approach (docking of all 202 inhibitors to all 222 PR structures) using Autodock Vina was implemented. The protease structures were clustered using a Kohonen self-organization map analysis of the data matrix of docking energies. The obtained clusters of PRs were correlated with the x-y-z coordinates of the PR structures to identify structural segments underlying this clustering. The PR structures were clustered into 4 classes. One of these classes exhibits rather strong binding with almost all inhibitors, while another class exhibits rather weak binding. The remaining two classes are intermediate in binding strength. The selectivity ratio indices for the carbon-alpha atoms of the PR structures indicate that conformational motion of residues outside the binding pocket contributes significantly to the discrimination of the 4 classes.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmgm.2019.06.011DOI Listing

Publication Analysis

Top Keywords

hiv-1 protease
8
202 inhibitors
8
structures clustered
8
structures
6
binding
5
classes
5
relationship docking
4
docking scores
4
scores protein
4
protein conformational
4

Similar Publications

Maturation inhibitors (MIs) block HIV-1 maturation by preventing the cleavage of the capsid protein and spacer peptide 1 (CA-SP1). Bevirimat (BVM), a first-in-class MI, displayed sub-optimal efficacy in clinical trials due to presence of SP1:V7A polymorphism in the Gag protein.This polymorphism is inherently present in HIV-1 subtype C and conferred resistance to BVM.

View Article and Find Full Text PDF

Background: Lenacapavir is a highly potent first-in-class inhibitor of HIV-1 capsid approved for the treatment of heavily treatment-experienced (HTE) people with HIV-1 (PWH) harboring multidrug resistant (MDR) virus, in combination with an optimized background regimen (OBR). Resistance analyses conducted after 2 years of lenacapavir treatment in the phase 2/3 CAPELLA study are described.

Methods: CAPELLA enrolled viremic HTE PWH with resistance to 2 or more drugs per class in at least 3 of the 4 main drug classes.

View Article and Find Full Text PDF

Objectives: We investigated the prevalence of drug resistance mutations (DRMs) in individuals newly diagnosed with HIV-1 in Estonia in 2020 and 2022, and in Ukrainian war refugees living with HIV who arrived in Estonia in 2022.

Methods: HIV-1 genomic RNA was sequenced in protease-reverse transcriptase and integrase regions. DRMs were determined separately by Stanford University CPR Tool and HIVdb Program.

View Article and Find Full Text PDF

Treatment options for viral infections are limited and viruses have proven adept at evolving resistance to many existing therapies, highlighting a significant vulnerability in our defenses. In response to this challenge, we explored the modulation of cellular RNA metabolic processes as an alternative paradigm to antiviral development. Previously, the small molecule 5342191 was identified as a potent inhibitor of HIV-1 replication by altering viral RNA accumulation at doses that minimally affect host gene expression.

View Article and Find Full Text PDF

The recent spread of SARS-CoV-2 has led to serious concerns about newly emerging infectious coronaviruses. Drug repurposing is a practical method for rapid development of antiviral agents. The viral spike protein of SARS-CoV-2 binds to its major receptor ACE2 to promote membrane fusion.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!